Uncoupling of the allosteric signalling network in the β1-adrenergic receptor by a negative allosteric modulator

Abstract Allosteric modulation is a fundamental aspect of G protein-coupled receptor (GPCR) regulation where molecules that bind to alternative sites outside the orthosteric pocket alter agonist-induced signalling responses. The advantages of allosteric modulators over traditional orthosteric agonists have positioned them as highly promising therapeutic agents. GPCRs exist in tuneable equilibria between multiple functional states, yet the ways in which allosteric modulators reshape these equilibria remain incompletely understood. Here we characterise how changes to the allosteric signalling network influence the conformational dynamics of the β 1 -adrenergic receptor (β 1 AR) through mutations at the E130 3.41 position or using the negative allosteric modulator, AS408. Both act through a known transmembrane (TM)3-TM4-TM5 site, reducing signalling to similar extents, but through distinct molecular mechanisms as revealed by pharmacological assays, MD simulations, and solution nuclear magnetic resonance spectroscopy. E130 3.41 mutations reduce agonist-stimulated signalling as a side chain-dependent rheostat, shifting receptor equilibria to populate states with weaker G protein affinities. In contrast, AS408 uncouples the intracellular region of β 1 AR from the influence of the orthosteric pocket and reduces G protein coupling by adoption of an alternative signalling-incompetent intracellular surface arrangement. Our investigations emphasise the relevance of mechanistic understanding in drug development and the importance of dynamics in GPCR allostery.